Cellectar Biosciences, Inc. (CLRB)
1.78
-0.09
(-4.81%)
USD |
NASDAQ |
Oct 02, 16:00
1.82
+0.04
(+2.25%)
After-Hours: 20:00
Cellectar Biosciences Max Drawdown (5Y) : 99.68% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.68% |
| August 31, 2026 | 99.68% |
| July 31, 2026 | 99.68% |
| June 30, 2026 | 99.68% |
| May 31, 2026 | 99.68% |
| April 30, 2026 | 99.68% |
| March 31, 2026 | 99.68% |
| February 28, 2026 | 99.68% |
| January 31, 2026 | 99.68% |
| December 31, 2025 | 99.68% |
| November 30, 2025 | 99.66% |
| October 31, 2025 | 99.61% |
| September 30, 2025 | 99.48% |
| August 31, 2025 | 99.66% |
| July 31, 2025 | 99.66% |
| June 30, 2025 | 99.66% |
| May 31, 2025 | 99.71% |
| April 30, 2025 | 99.71% |
| March 31, 2025 | 99.71% |
| February 28, 2025 | 99.71% |
| January 31, 2025 | 99.71% |
| December 31, 2024 | 99.71% |
| November 30, 2024 | 99.71% |
| October 31, 2024 | 99.71% |
| September 30, 2024 | 99.71% |
| Date | Value |
|---|---|
| August 31, 2024 | 99.71% |
| July 31, 2024 | 99.71% |
| June 30, 2024 | 99.71% |
| May 31, 2024 | 99.72% |
| April 30, 2024 | 99.75% |
| March 31, 2024 | 99.75% |
| February 29, 2024 | 99.77% |
| January 31, 2024 | 99.79% |
| December 31, 2023 | 99.82% |
| November 30, 2023 | 99.85% |
| October 31, 2023 | 99.85% |
| September 30, 2023 | 99.85% |
| August 31, 2023 | 99.85% |
| July 31, 2023 | 99.85% |
| June 30, 2023 | 99.85% |
| May 31, 2023 | 99.85% |
| April 30, 2023 | 99.85% |
| March 31, 2023 | 99.85% |
| February 28, 2023 | 99.85% |
| January 31, 2023 | 99.85% |
| December 31, 2022 | 99.85% |
| November 30, 2022 | 99.85% |
| October 31, 2022 | 99.85% |
| September 30, 2022 | 99.85% |
| August 31, 2022 | 99.85% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Savara, Inc. | 93.79% |
| Vericel Corp. | 73.97% |
| Biogen, Inc. | 72.66% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -72.93 |
| Beta (5Y) | 0.5811 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 79.60% |
| Historical Sharpe Ratio (5Y) | -0.8431 |
| Historical Sortino (5Y) | -1.190 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 42.22% |